Company Overview and News

 
Sri Lanka secures US $ 50mn ADB loan for roof top solar

7h dailymirror.lk
Sri Lanka has secured a US $ 50 million loan from the Asian Development Bank (ADB) for rooftop solar power generation project under the much hyped ‘Soorya bala sangramaya’ or battle for solar power programme.
FISI ATB FIISO FIISP

 
High-level panel on stressed power assets holds 2nd meet, RBI remains absent

2018-09-14 moneycontrol
The Power Ministry gave a detailed presentation to a high-level empowered committee on measures to deal with problems of struggling power assets, a source said.
FISI FIISO FIISP

 
Why Is Manulife (MFC) Down 3.6% Since Last Earnings Report?

2018-09-07 zacks
A month has gone by since the last earnings report for Manulife Financial (MFC - Free Report) . Shares have lost about 3.6% in that time frame, underperforming the S&P 500.
FISI TGI FIISO FIISP MFC 0945 ALLY KORS MFC

 
Laurentian Bank Financial Group reports third quarter 2018 results

2018-09-04 globenewswire
François Desjardins, President and Chief Executive Officer, commented on the resolution of the mortgage loan portfolio review: “We have now completed our mortgage loan portfolio review and have resolved the situation with both CMHC and the third-party purchaser, with no impact on our customers. The review was completed within the guidance given last quarter. This has been a tremendous learning experience and in the end, makes us stronger and more determined than ever to become a renewed financial institution, committed to being different and better and to deliver value to our customers.
FISI FIISO LB FIISP

 
Sporting community mourns passing of young Olympian Ian ‘Yanyan’ Lariba

2018-09-03 bworldonline
THE local sporting community is mourning the passing of young Olympian Ian “Yanyan” Lariba, who lost her battle with leukemia late Sunday night. She was 23.
FISI FIISO FIISP

 
Why Is American Financial (AFG) Down 2.2% Since Last Earnings Report?

2018-08-31 zacks
A month has gone by since the last earnings report for American Financial Group (AFG - Free Report) . Shares have lost about 2.2% in that time frame, underperforming the S&P 500.
FISI AFG AFW ADRO AFGE AFA FIISO FIISP AFGH

4
An evening walk down Dalal Street | Nifty jittery ahead of FO expiry, Sensex sheds 38,750; midcaps gain

2018-08-29 moneycontrol
A sharp selloff in the last hour of trade weighed on equity benchmarks on Wednesday, with the Nifty giving up 11,700-mark. Weakness among giant index names such as Reliance Industries, HDFC Bank, and Infosys, among others, dragged the market lower as well.
500325 500228 RELIANCE 532832 533278 CADILAHC 532321 RIGD HDFCBANK BJJQY CLNDY RLNIY 500034 SBAZ FISI 532627 FIISO FIISP JSWSTEEL CDLYY BRK.A BAJFINANCE HDB 500180 JPPOWER COALINDIA IBREALEST

3
JP Power Ventures up 11% as board to consider loan conversion of Rs 4000cr

2018-08-29 moneycontrol
Shares of Jaiprakash Power Ventures added more than 11 percent intraday Wednesday as company to consider loan conversion into preference shares.
BRK.A FISI 532627 JPPOWER FIISO FIISP

 
Escudero seeks Senate probe into Nayong Pilipino’s $1.5-billion resort project

2018-08-29 newsinfo.inquirer.net
Senator Francis Escudero is seeking a Senate probe into corruption allegations against former officials of the Nayong Pilipino Foundation (NPF) over its $1.5-billion resort project with a Hong Kong firm in Parañaque City.
FISI FIISO FIISP

 
Financial Institutions, Inc. Announces Quarterly Cash Dividend

2018-08-22 globenewswire
WARSAW, N.Y., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Financial Institutions, Inc. (the “Company”) (NASDAQ: FISI) announced today that its Board of Directors has approved a quarterly cash dividend of $0.24 per outstanding common share. The Company also announced dividends of $0.75 per share on its Series A 3% preferred stock and $2.12 per share on its Series B-1 8.48% preferred stock. All dividends are payable October 2, 2018, to shareholders of record on September 13, 2018.
FISI FIISO FIISP

 
SmartMetric Says Research Reveals Banks Suffer Substantial Card Transaction Losses As A Direct Result Of Card Fraud With 56% of Consumers Changing Card Usage After Experiencing A Card Fraud

2018-08-22 globenewswire
NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- SmartMetric, Inc. (OTCQB:SMME) – A more secure credit card not only provides peace of mind to the card-using consumer but avoids the substantial financial impact to card-issuing banks from losing card-transaction business to a competitor bank's card in the card user's wallet.
FISI SMME ACIW FIISO FIISP

 
New Mandatory Risk Rating Is Misleading Canadian Investors

2018-08-20 seekingalpha
New mandatory risk weighting system implemented in September 2017 based on 10-year Standard Deviation putting Canadian investors at risk.
FISI FIISO FIISP

 
ECN Capital Corp. (ECNCF) CEO Steven Hudson on Q2 2018 Results - Earnings Call Transcript

2018-08-13 seekingalpha
Thank you for standing by. This is the conference operator. Welcome to the ECN Capital Second Quarter 2018 conference call. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. [Operator Instructions].
FISI FIISO ECNCF FIISP PTCI

 
Manulife (MFC) Q2 Earnings Improve on Solid Segment Results

2018-08-09 zacks
Manulife Financial Corporation (MFC - Free Report) delivered second-quarter 2018 core earnings of $1.11 billion (C$1,431 million), up 23.3% year over year. This upside stemmed from double-digit core earnings growth across all operating segments as well as solid net income.
FISI GD ZTO PGR FIISO FIISP MTG MFC 0945 MFC RLI

 
Option to interim dividend from RBI is open: Subhash Garg

2018-08-09 moneycontrol
The option of interim dividend from the Reserve Bank of India during the financial year is open and decision in this regard may be taken later this year, Economic Affairs Secretary S C Garg said on Thursday.
FISI FIISO FIISP

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...